Immutep Ltd (IMMP)
2.51
+0.19
(+8.19%)
USD |
NASDAQ |
Apr 23, 16:00
2.83
+0.32
(+12.75%)
After-Hours: 05:07
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 298.40M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 53.99% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.55% |
Profile
| Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products. |
| URL | https://www.immutep.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products. |
| URL | https://www.immutep.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |